Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, et al.
Blood (2019) Vol. 134, Iss. 21, pp. 1811-1820
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Michael Hallek, Othman Al‐Sawaf
American Journal of Hematology (2021) Vol. 96, Iss. 12, pp. 1679-1705
Open Access | Times Cited: 280
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 8, pp. 559-577
Open Access | Times Cited: 135
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 15, pp. 1609-1618
Open Access | Times Cited: 133
The landscape overview of CD47-based immunotherapy for hematological malignancies
Hua Yang, Yang Xun, Hua You
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 58
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
Carla Rizzo, Sara Amata, Ivana Pibiri, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7728-7728
Open Access | Times Cited: 50
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
Michael Hallek
American Journal of Hematology (2025)
Open Access | Times Cited: 2
Advances in targeted therapy for malignant lymphoma
Li Wang, Wei Qin, Yujia Huo, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 102
Umbralisib: First Approval
Sohita Dhillon, Susan J. Keam
Drugs (2021) Vol. 81, Iss. 7, pp. 857-866
Closed Access | Times Cited: 56
CLL update 2022: A continuing evolution in care
Neil E. Kay, Paul J. Hampel, Daniel L. Van Dyke, et al.
Blood Reviews (2022) Vol. 54, pp. 100930-100930
Closed Access | Times Cited: 39
Small-molecule agents for cancer immunotherapy
Fang Wang, Kai Fu, Yujue Wang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 3, pp. 905-952
Open Access | Times Cited: 22
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J. Nastoupil, Matthew A. Lunning, Julie M. Vose, et al.
The Lancet Haematology (2019) Vol. 6, Iss. 2, pp. e100-e109
Closed Access | Times Cited: 68
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 55
Targeting Casein Kinase 1 (CK1) in Hematological Cancers
Pavlína Janovská, Emmanuel Normant, Hari P. Miskin, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 23, pp. 9026-9026
Open Access | Times Cited: 55
Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma
Wendan Xu, Philipp Berning, Georg Lenz
Blood (2021) Vol. 138, Iss. 13, pp. 1110-1119
Open Access | Times Cited: 55
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Núria Profitós-Pelejà, Juliana C. Santos, Ana Marín‐Niebla, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 860-860
Open Access | Times Cited: 36
PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
Iwona Hus, Bartosz Puła, Tadeusz Robak
Cancers (2022) Vol. 14, Iss. 6, pp. 1571-1571
Open Access | Times Cited: 31
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Sigrid S. Skånland, Jennifer R. Brown
Haematologica (2022) Vol. 108, Iss. 1, pp. 9-21
Open Access | Times Cited: 28
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
Moritz Fürstenau, Barbara Eichhorst
Cancers (2021) Vol. 13, Iss. 6, pp. 1336-1336
Open Access | Times Cited: 36
Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
Yan Yang, Yang Zheng, Yun Yang
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 33
Targeting PI3K in Cancer Treatment: A Comprehensive Review with Insights from Clinical Outcomes
Munier Hossain, Md. Arafat Hossain
European Journal of Pharmacology (2025), pp. 177432-177432
Closed Access
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
Ioannis Kyriakidis, Eleni Vasileiou, Claudia Rössig, et al.
Journal of Fungi (2021) Vol. 7, Iss. 3, pp. 186-186
Open Access | Times Cited: 27
Novel insights into histone lysine methyltransferases in cancer therapy: From epigenetic regulation to selective drugs
Qi-Li Liao, Jie Yang, Shengfang Ge, et al.
Journal of Pharmaceutical Analysis (2022) Vol. 13, Iss. 2, pp. 127-141
Open Access | Times Cited: 20
Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Tycel Phillips, Jean‐Marie Michot, Vincent Ribrag
Clinical Lymphoma Myeloma & Leukemia (2020) Vol. 21, Iss. 1, pp. 8-20.e3
Open Access | Times Cited: 28
Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
Francesca Perutelli, Rebecca Jones, Valentina Griggio, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
Phosphatidylinositol 3 Kinase δ Inhibitors
Jennifer R. Brown
The Cancer Journal (2019) Vol. 25, Iss. 6, pp. 394-400
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top